Vpr14-88-Apobec3G fusion protein is efficiently incorporated into vif-positive HIV-1 particles and inhibits viral infection

PLoS ONE

Volumn 3, Issue 4, 2008, Pages

  Ao, Zhujun ^a   Yu, Zhe ^a   Wang, Lina ^a,b   Zheng, Yingfeng ^a   Yao, Xiaojian ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Center for Disease Prevention and Control   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CHEMOKINE RECEPTOR CCR5; COMPLEMENTARY DNA; HYBRID PROTEIN; LENTIVIRUS VECTOR; VIF PROTEIN; VIRUS DNA; VPR PROTEIN; VPR14 88 APOBEC3G FUSION PROTEIN; APOBEC3G PROTEIN, HUMAN; CYTIDINE DEAMINASE; VPR PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DNA SYNTHESIS; GENETIC TRANSDUCTION; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION SENSITIVITY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION; TRANSIENT EXPRESSION; VIRION; VIRUS INHIBITION; VIRUS PARTICLE; VIRUS REPLICATION; CELL LINE; CHEMISTRY; GENETIC TRANSCRIPTION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MONONUCLEAR CELL; MUTATION; PLASMID; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1; VESICULAR STOMATITIS VIRUS;

CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CYTIDINE DEAMINASE; GENE PRODUCTS, VIF; HELA CELLS; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MUTATION; PLASMIDS; RECOMBINANT FUSION PROTEINS; TRANSCRIPTION, GENETIC; VPR GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 44849100325     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001995     Document Type: Article

References (71)

1. Sheehy AM, Gaddis NC, Choi JD, Malim MH (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418: 646-650.
2. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, et al. (2003) The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424: 94-98.
3. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, et al. (2003) DNA deamination mediates innate immunity to retroviral infection. Cell 113: 803-809.
4. Lecossier D, Bouchonnet F, Clavel F, Hance AJ (2003) Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300: 1112.
5. Mangeat B, Turelli P, Caron G, Friedli M, Perrin I, et al. (2003) Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424: 99-103.
6. Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, et al. (2003) Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114: 21-31.
7. Chiu YL, Soros VB, Kreisberg JF, Stopak K, Yonemoto W, et al (2005) Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature 435: 108-114.
8. Newman EN, Holmes RK, Craig HM, Klein KC, Lingappa JR, et al. (2005) Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr Biol 15: 166-170.
9. Cen S, Guo F, Niu M, Saadatmand J, Deflassieux J, et al. (2004) The interaction between HIV-1 Gag and APOBEC3G. J Biol Chem 279: 33177-84.
10. Alce TM, Popik W (2004) APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein. J Biol Chem 279: 34083-34086.
11. Doehle BP, Schafer A, Wiegand HL, Bogerd HP, Cullen BR (2005) Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion. J Virol 79: 8201-8207.
12. Luo K, Liu B, Xiao Z, Yu Y, Yu Y, et al. (2004) Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J Virol 78: 11841-11852.
13. Schafer A, Bogerd HP, Cullen BR (2004) Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology 328: 163-168.
14. Svarovskaia ES, Xu H, Mbisa JL, Barr R, Gorelick RJ, et al. (2004) Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APO-BEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J Biol Chem 279: 35822-35828.
15. Zennou V, Perez-Caballero D, Gottlinger H, Bieniasz PD (2004) APOBEC3G incorporation into human immunodeficiency virus type 1 particles. J Virol 78: 12058-12061.
16. Burnett A, Spearman P (2007) APOBEC3G multimers are recruited to the plasma membrane for packaging into human immunodeficiency virus type 1 virus-like particles in an RNA-dependent process requiring the NC basic linker. J Virol 81: 5000-5013.
17. Stopak K, de Noronha C, Yonemoto W, Greene WC (2003) HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell 12: 591-601.
18. Sheehy AM, Gaddis NC, Malim MH (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 9: 1404-1407.
19. Marin M, Rose KM, Kozak SL, Kabat D (2003) HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 9: 1398-1403.
20. Yu X, Yu Y, Liu B, Luo K, Kong W, et al. (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cu15-SCF complex. Science 302: 1056-1060.
21. Yu Y, Xiao Z, Ehrlich ES, Yu X, Yu XF (2004) Selective assembly of HIV-1 Vif-Cu15-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev 18: 2867-2872.
22. Kao S, Khan MA, Miyagi E, Plishka R, Buckler-White A, et al. (2003) The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J Virol 77: 11398-11407.
23. Conticello SG, Harris RS, Neuberger MS (2003) The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol 13: 2009-2013.
24. Kao S, Miyagi E, Khan MA, Takeuchi H, Opi S, et al. (2004) Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells. Retrovirology 1: 27.
25. Kan S, Goila-Gaur R, Miyagi E, Khan MA, Opi S, et al. (2007) Production of infectious virus and degradation of APOBEC3G are separable functional properties of human immunodeficiency virus type 1 Vif. Virology 369: 329-339.
26. Opi S, Kao S, Goila-Gaur R, Khan MA, Miyagi E, et al. (2007) Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant. J Virol 81: 8236-8246.
27. Bogerd HP, Doehle BP, Wiegand HL, Cullen BR (2004) A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc Natl Acad Sci U S A 101: 3770-3774.
28. Mangeat B, Turelli P, Liao S, Trono D (2004) A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J Biol Chem 279: 14481-14483.
29. Schrofelbauer B, Chen D, Landau NR (2004) A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc Natl Acad Sci U S A 101: 3927-3932.
30. Xu H, Svarovskaia ES, Barr R, Zhang Y, Khan MA, et al. (2004) A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc Natl Acad Sci U S A 101: 5652-5657.
31. Huthoff H, Malim MH (2007) Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation. J Virol 81: 3807-3815.
32. Yao XJ, Subbramanian RA, Rougeau N, Boisvert F, Bergeron D, et al. (1995) Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localizatton and virion incorporation. J Virol 69: 7032-7044.
33. Paxton W, Connor RI, Landau NR (1993) Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of Gag and mutational analysis. J. Virol. 67: 7229-7237.
34. Lu YL, Spearman P, Ratner L (1993) Human immunodeficiency vim type 1 viral protein R localization in infected cells and virions. J Virol 67: 6542-6550.
35. Kondo E, Mammano F, Cohen EA, Gottlinger HG (1995) The p6gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles. J Virol 69: 2759-2764.
36. Lavallee C, Yao XJ, Ladha A, Gottlinger H, Haseltine WA, et al. (1994) Requirement of the Pr55gag precursor for incorporation of the Vpr product into human immunodeficiency virus type 1 viral particles. J Virol 68: 1926-1934.
37. Wu X, Liu H, Xiao H, Kim J, Seshaiah P, et al. (1995) Targeting foreign proteins to human immunodeficiency virus particles via fusion with Vpr and Vpx. J Virol 69: 3389-3398.
38. Wu X, Liu H, Xiao H, Kappes JC (1996) Proteolytic activity of human immunodeficiency virus Vpr- and Vpx-protease fusion proteins. Virology 219: 307-313.
39. Wu X, Liu H, Xiao H, Conway JA, Hunter E, et al. (1997) Functional RT and IN incorporated into HIV-1 particles independently of the Gag/Pol precursor protein. Embo J 16: 5113-5122.
40. Kobinger GP, Borsetti A, Nie Z, Mercier J, Daniel N, et al. (1998) Virion-targeted viral inactivation of human immunodeficiency virus type 1 by using Vpr fusion proteins. J Virol 72: 5441-5448.
41. Yao XJ, Kobinger G, Dandache S, Rougeau N, Cohen E (1999) HIV-1 Vpr-chloramphenicol acetyltransferase fusion proteins: sequence requirement for virion incorporation and analysis of antiviral effect. Gene Ther 6: 1590-1599.
42. Fletcher TM 3rd, Soares MA, McPhearson S, Hui H, Wiskerchen M, et al. (1997) Complementation of integrase function in HIV-1 virions. Embo J 16: 5123-5138.
43. Park IW, Sodroski J (1996) Targeting a foreign protein into virion particles by fusion with the Vpx protein of simian immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol 11: 341-350.
44. Ao Z, Yao X, Cohen EA (2004) Assessment of the role of the central DNA flap in human immunodeficiency virus type 1 replication by using a single-cycle replication system. J Virol 78: 3170-3177.
45. Kimpton J, Emerman M (1992) Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated b-galactosidase gene. J Virol 66: 2232-2239.
46. Nguyen KL, Ilano M, Akari H, Miyagi E, Poeschla EM, et al. (2004) Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA and allows for highly efficient Rev-independent expression. Virology 319: 163-175.
47. Bishop KN, Holmes RK, Malim MH (2006) Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J Virol 80: 8450-8458.
48. Holmes RK, Koning FA, Bishop KN, Malim MH (2007) APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J Biol Chem 282: 2587-2595.
49. Yang Y, Guo F, Cen S, Kleiman L (2007) Inhibition of initiation of reverse transcription in HIV-1 by human APOBEC3F. Virology.
50. Ao Z, Fowke KR, Cohen EA, Yao X (2005) Contribution of the C-terminal trilysine regions of human immunodeficiency virus type 1 integrase for efficient reverse transcription and viral DNA nuclear import. Retrovirology 2: 62.
51. Kobinger GP, Weiner DJ, Yu QC, Wilson JM (2001) Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nat Biotechnol 19: 225-230.
52. Levy DN, Fernandes LS, Williams WV, Weiner DB (1993) Induction of cell differentiation by human immunodeficiency virus 1 vpr. Cell 72: 541-550.
53. Rogel ME, Wu LI, Emerman M (1995) The human immunodeficiency virus type 1 Vpr gene prevents cell proliferation during chronic infection. J. Virol. 69: 882-888.
54. He J, Choe S, Walker R, Di Marzio P, Morgan DO, et al. (1995) Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol 69: 6705-6711.
55. Re F, Braaten D, Franke EK, Luban J (1995) Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B. J. Virol. 69: 6859-6864.
56. Yao XJ, Mouland AJ, Subbramanian RA, Forget J, Rougeau N, et al. (1998) Vpr stimulates viral expression and induces cell killing in human immunodeficiency virus type 1-infected dividing Jurkat T cells. J Virol 72: 4686-4693.
57. Mehle A, Strack B, Ancuta P, Zhang C, McPike M, et al. (2004) Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J Biol Chem 279: 7792-7798.
58. Aguiar RS, Lovsin N, Tanuri A, Peterlin BM (2007) VPR.A3A chimera inhibits HIV replication. J Biol Chem.
59. Goncalves J, Korin Y, Zack J, Gabuzda D (1996) Role of Vif in human immunodeficiency virus type 1 reverse transcription. J Virol 70: 8701-8709.
60. Li J, Potash MJ, Volsky DJ (2004) Functional domains of APOBEC3G required for antiviral activity. J Cell Biochem 92: 560-572.
61. Guo F, Cen S, Niu M, Yang Y, Gorelick RJ, et al. (2007) The interaction of APOBEC3G with HIV-1 nucleocapsid inhibits tRNALys3 annealing to viral RNA. J Virol.
62. Guo F, Cen S, Niu M, Saadatmand J, Kleiman L (2006) Inhibition of formula-primed reverse transcription by human APOBEC3G during human immuno-deficiency virus type 1 replication. J Virol 80: 11710-11722.
63. Kreisberg JF, Yonemoto W, Greene WC (2006) Endogenous factors enhance HIV infection of tissue naive CD4 T cells by stimulating high molecular mass APOBEC3G complex formation. J Exp Med 203: 865-870.
64. Popov S, Rexach M, Zybarth G, Reiling N, Lee M-A, Ratner L, Lane CM, Moore MS, Blobel G, Bukrinsky M (1998) Viral protein R regulates nuclear import of HIV-1 pre-integration complex. EMBO J. 17: 909-917.
65. Coker HA, Petersen-Mahrt SK (2007) The nuclear DNA deaminase AID functions distributively whereas cytoplasmic APOBEC3G has a processive mode of action. DNA Repair (Amst) 6: 235-243.
66. Petersen-Mahrt S (2005) DNA deamination in immunity. Immunol Rev 203: 80-97.
67. Ao Z, Huang G, Yao H, Xu Z, Labine M, et al. (2007) Interaction of human immunodeficiency virus type 1 integrase with cellular nuclear import receptor importin 7 and its impact on viral replication. J Biol Chem 282: 13456-13467.
68. Cohen GB, Gandhi RT, Davis DM, Mandelboim O, Chen BK, et al. (1999) The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 10: 661-671.
69. Yao XJ, Friborg J, Checroune F, Gratton S, Boisvert F, et al. (1995) Degradation of CD4 induced by human immunodeficiency virus type 1 Vpu protein: a predicted alpha-helix structure in the proximal cytoplasmic region of CD4 contributes to Vpu sensitivity. Virology 209: 615-623.
70. Yao XJ, Mouland AJ, Subbramanian RA, Forget J, Rougreau N, et al. (1998) Vpr stimulates viral expression and induces cell killing in human immunodeficiency virus type 1-infected dividing Jurkat T cells. J Virol 72: 4686-4693.
71. Simon JHM, Malim MH (1996) The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes. J. Virol. 70: 5297-5305.